Pharmaceutical giant AstraZeneca PLC said Thursday it has reached an agreement with Aspen Pharmacare Holdings Ltd. giving the Johannesburg-listed company rights to its anesthetics portfolio outside the U.S.
Under the deal, Aspen Global Incorporated, a unit of Aspen Pharmacare, will buy commercialization rights outside the U.S. to the portfolio for an upfront payment of $520 million.
Aspen will also pay AstraZeneca up to $250 million in a product sales-related payment, as well as double-digit percentage trademark royalties on product sales.
AstraZeneca said it will manufacture and supply the products on a cost plus basis to Aspen for an initial period of 10 years. Upon completion, Aspen will assume responsibility for all activities relating to the sale of the portfolio in all relevant markets, AstraZeneca added.
The deal isn’t expected to impact AstraZeneca’s financial guidance this year, the company said.
By Ian Walker
Source: MarketWatch
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
